<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363697</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00078</org_study_id>
    <nct_id>NCT04363697</nct_id>
  </id_info>
  <brief_title>Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure DAPAgliflozin and Effect on Cardiovascular Events in ACuTe Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The TIMI Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, multicenter, parallel-group, randomized, double-blind,&#xD;
      placebo-controlled trial in patients with heart failure with reduced ejection fraction (left&#xD;
      ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization&#xD;
      for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin&#xD;
      versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular (CV) death or worsening heart failure</measure>
    <time_frame>2 months</time_frame>
    <description>Time to first occurrence of CV death or worsening heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite CV death, rehospitalization for heart failure, urgent heart failure visit</measure>
    <time_frame>2 months</time_frame>
    <description>Time to first occurrence of composite of CV death, rehospitalization for heart failure, or urgent heart failure visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite CV death, rehospitalization for heart failure</measure>
    <time_frame>2 months</time_frame>
    <description>Time to first occurrence of composite of CV death or rehospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for heart failure, urgent heart failure visit</measure>
    <time_frame>2 months</time_frame>
    <description>Time to first occurrence of rehospitalization for heart failure or urgent heart failure visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>2 months</time_frame>
    <description>Readmission within 30 days of hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV death</measure>
    <time_frame>2 months</time_frame>
    <description>Time to CV death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>2 months</time_frame>
    <description>Time to death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Symptomatic hypotension</measure>
    <time_frame>2 months</time_frame>
    <description>Symptomatic hypotension leading to hospitalization or study drug discontinuation</description>
  </other_outcome>
  <other_outcome>
    <measure>Worsening renal function</measure>
    <time_frame>2 months</time_frame>
    <description>Worsening renal function resulting in at least a doubling of serum creatinine (sCr), hospitalization, study drug discontinuation, dialysis, or renal death</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Acute Heart Failure</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg administered orally once daily for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally once daily for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years (male or female)&#xD;
&#xD;
          2. Currently hospitalized for acute heart failure (AHF) defined as meeting all the&#xD;
             following criteria:&#xD;
&#xD;
               1. Presentation with worsening symptoms of heart failure (e.g., worsening dyspnea or&#xD;
                  dyspnea at rest, progressive fatigue, rapid weight gain, worsening&#xD;
                  edema/abdominal distention/anasarca)&#xD;
&#xD;
               2. Objective signs or diagnostic testing consistent with volume overload (e.g.,&#xD;
                  jugular venous distension, pulmonary basilar crackles, S3 gallop, ascites,&#xD;
                  hepatomegaly, peripheral edema, radiological evidence of pulmonary congestion,&#xD;
                  noninvasive or invasive hemodynamic evidence of elevated filling pressures)&#xD;
&#xD;
               3. Intensification of heart failure therapy during admission defined as at least one&#xD;
                  of the following:&#xD;
&#xD;
             i. Augmentation of oral diuretic therapy [e.g., ≥2x outpatient regimen dose, addition&#xD;
             of a second diuretic agent, or new initiation of diuretic therapy in a previously&#xD;
             naïve patient] ii. Initiation of intravenous diuretic therapy iii. Initiation of&#xD;
             intravenous vasoactive agent (e.g., inotrope or vasodilator)&#xD;
&#xD;
             The majority of enrolled patients should have an established history of heart failure&#xD;
             with reduced ejection fraction (HFrEF) (defined as present for ≥2 months and for which&#xD;
             the patient is on treatment). Trial leadership will monitor this proportion and may&#xD;
             cap enrollment of patients without an established history of HFrEF (i.e., patients&#xD;
             presenting with de novo HFrEF).&#xD;
&#xD;
          3. Most recent LVEF ≤40% within the past 12 months (including current hospitalization)&#xD;
&#xD;
          4. Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) (≥1600 pg/mL) or B-type&#xD;
             natriuretic peptide (BNP) (≥400 pg/mL) during current hospitalization (NT-proBNP ≥2400&#xD;
             pg/mL or BNP ≥600 pg/mL if patient in atrial fibrillation) (NB: for patients treated&#xD;
             with angiotensin receptor neprilysin inhibitor (ARNI) in the 4 weeks prior to&#xD;
             randomization, only NT-proBNP values should be used)&#xD;
&#xD;
          5. Eligible patients will be randomized no earlier than 24 hours and up to seven days&#xD;
             after presentation while still hospitalized once they have been stabilized, as defined&#xD;
             by:&#xD;
&#xD;
               1. No increase (i.e., intensification) in the dose of intravenous diuretics during&#xD;
                  the 24 hours prior to randomization&#xD;
&#xD;
               2. No use of intravenous vasodilators or inotropes during the 24 hours prior to&#xD;
                  randomization&#xD;
&#xD;
        Patients with and without type 2 diabetes are eligible for participation in the trial. The&#xD;
        trial leadership will monitor the proportion of patients with and without type 2 diabetes&#xD;
        and may cap enrollment of one subgroup to ensure adequate representation of the other.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic hypotension in the past 24 hours&#xD;
&#xD;
          2. Use of two or more inotropic agents during the index hospitalization&#xD;
&#xD;
          3. Estimated glomerular filtration rate (eGFR) &lt;30 ml/min/1.73 m2 as measured by the&#xD;
             Chronic kidney disease epidemiology collaboration equation (CKD-EPI) equation at&#xD;
             screening or rapidly progressive renal disease&#xD;
&#xD;
          4. Use of an Sodium-glucose cotransporter-2 (SGLT2) inhibitor within the last 30 days&#xD;
&#xD;
          5. Prior intolerance of SGLT2 inhibitors&#xD;
&#xD;
          6. Type 1 diabetes mellitus or history of diabetic ketoacidosis&#xD;
&#xD;
          7. In patients with diabetes on insulin or a sulfonylurea, a history of recurrent major&#xD;
             hypoglycemia (i.e., resulting in severe impairment in consciousness or behavior, or&#xD;
             requiring emergency external assistance)&#xD;
&#xD;
          8. Implantation of a cardiac resynchronization therapy (CRT) device or valve repair or&#xD;
             replacement within 3 months prior to randomization or intent to do so during the trial&#xD;
&#xD;
          9. ST-segment elevation myocardial infarction or coronary revascularization (percutaneous&#xD;
             coronary intervention or coronary artery bypass grafting) within 3 months prior to&#xD;
             randomization or intent to undergo coronary revascularization during the trial&#xD;
&#xD;
         10. Untreated sustained ventricular arrhythmias or Mobitz type II or third-degree heart&#xD;
             block (i.e., without an implantable cardioverter defibrillator [ICD] or pacemaker,&#xD;
             respectively)&#xD;
&#xD;
         11. History of heart transplantation, current transplant listing, or history of mechanical&#xD;
             circulatory support (either durable or temporary)&#xD;
&#xD;
         12. History of heart failure due to restrictive or infiltrative cardiomyopathy, active&#xD;
             myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy,&#xD;
             uncorrected primary valvular disease, or complex congenital heart disease&#xD;
&#xD;
         13. History of cirrhosis with evidence of portal hypertension&#xD;
&#xD;
         14. Women of child-bearing potential (unless using adequate contraception) or currently&#xD;
             breastfeeding&#xD;
&#xD;
         15. Current participation in a clinical trial with an unlicensed drug or device&#xD;
&#xD;
         16. Study center employees or their family members&#xD;
&#xD;
         17. Any condition that, in the opinion of the investigator, would make trial participation&#xD;
             not in the best interest of the subject, or would compromise compliance with the trial&#xD;
             protocol (e.g., active severe infection, active malignancy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abby Cange</last_name>
    <phone>800-385-4444</phone>
    <email>acange@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>TIMI Study Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TIMI Study Group</last_name>
      <phone>617-278-0145</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

